DE60112429D1 - Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen - Google Patents

Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen

Info

Publication number
DE60112429D1
DE60112429D1 DE60112429T DE60112429T DE60112429D1 DE 60112429 D1 DE60112429 D1 DE 60112429D1 DE 60112429 T DE60112429 T DE 60112429T DE 60112429 T DE60112429 T DE 60112429T DE 60112429 D1 DE60112429 D1 DE 60112429D1
Authority
DE
Germany
Prior art keywords
factor
pharmaceutical compounds
containing pharmaceutical
xiii
factor vii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60112429T
Other languages
English (en)
Other versions
DE60112429T2 (de
Inventor
Christian Petersen
Ulla Hedner
Rasmus Rojkjaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk Health Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care AG filed Critical Novo Nordisk Health Care AG
Application granted granted Critical
Publication of DE60112429D1 publication Critical patent/DE60112429D1/de
Publication of DE60112429T2 publication Critical patent/DE60112429T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE60112429T 2000-05-10 2001-05-10 Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen Expired - Lifetime DE60112429T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DK200000778 2000-05-10
DKPA200000778 2000-05-10
DKPA200000771 2000-05-10
DK200000771 2000-05-10
DK200000871 2000-06-06
DKPA200000871 2000-06-06
PCT/DK2001/000322 WO2001085198A1 (en) 2000-05-10 2001-05-10 tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII

Publications (2)

Publication Number Publication Date
DE60112429D1 true DE60112429D1 (de) 2005-09-08
DE60112429T2 DE60112429T2 (de) 2006-06-01

Family

ID=27222387

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60112429T Expired - Lifetime DE60112429T2 (de) 2000-05-10 2001-05-10 Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen
DE60115422T Expired - Fee Related DE60115422T2 (de) 2000-05-10 2001-05-10 PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60115422T Expired - Fee Related DE60115422T2 (de) 2000-05-10 2001-05-10 PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR

Country Status (17)

Country Link
US (3) US20030092627A1 (de)
EP (3) EP1282438B1 (de)
JP (2) JP2004505016A (de)
CN (1) CN1304049C (de)
AT (2) ATE311198T1 (de)
AU (3) AU2001258228B2 (de)
BR (1) BR0110659A (de)
CA (1) CA2406583A1 (de)
CZ (1) CZ20023667A3 (de)
DE (2) DE60112429T2 (de)
DK (1) DK1282438T3 (de)
ES (2) ES2254414T3 (de)
HU (1) HUP0301868A3 (de)
IL (1) IL152554A0 (de)
NO (1) NO20025355L (de)
PL (1) PL365042A1 (de)
WO (2) WO2001085199A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211886B1 (pl) * 1999-10-04 2012-07-31 Novartis Vaccines & Diagnostic Stabilizowana ciekła kompozycja farmaceutyczna, sposób zwiększania trwałości polipeptydu, sposób zwiększania trwałości podczas przechowywania kompozycji, sucha postać kompozycji oraz preparat zawierający kompozycję
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
CA2420892A1 (en) 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
JP4361728B2 (ja) 2000-09-13 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉ変異型
EP1337267B1 (de) * 2000-11-03 2007-04-25 ZymoGenetics, Inc. Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
ES2288524T3 (es) * 2000-11-10 2008-01-16 Zymogenetics, Inc. Factor xiii en combinacion con factor ix para tratar la hemofilia b.
PL365290A1 (en) * 2001-02-05 2004-12-27 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor ix polypeptides
EP1379271A1 (de) * 2001-02-21 2004-01-14 ZymoGenetics, Inc. Therapie des von willebrand syndroms
WO2003022305A1 (en) * 2001-09-10 2003-03-20 Zymogenetics, Inc. Method for treating coumarin-induced hemorrhage
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
WO2003039581A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
WO2003039582A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocapronic acid
HUP0402315A3 (en) * 2001-12-21 2009-03-30 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
KR101006070B1 (ko) * 2001-12-21 2011-01-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드의 액체 조성물
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
PT1599222E (pt) * 2003-01-08 2009-06-12 Novartis Vaccines & Diagnostic Composições aquosas estabilizadas que contêm um inibidor da via do factor tecidular (tfpi) ou uma variante do inibidor da via do factor tecidular
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
CA2534028A1 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
EP1750758A1 (de) * 2004-05-11 2007-02-14 Novo Nordisk Health Care AG Verwendung von faktor viia zur behandlung von verbrennungstraumata
WO2005115442A1 (en) * 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
WO2006021584A2 (en) * 2004-08-27 2006-03-02 Novo Nordisk Health Care Ag Purification of factor xiii polypeptides from biological materials
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
ATE540974T1 (de) 2004-11-23 2012-01-15 Zymogenetics Inc Reinigung des rekombinanten menschlichen faktors xiii
WO2006089966A2 (en) * 2005-02-28 2006-08-31 Novo Nordisk Health Care Ag Fxiii variants with improved properties
EP1919499A2 (de) * 2005-07-29 2008-05-14 Universiteit van Maastricht Regulierung von gewebefaktoraktivität durch proteine und tfpi (tissue factor pathway inhibitor)
DK2004214T3 (da) 2006-03-16 2013-02-18 Stellaris Pharmaceuticals Aps Lokalbehandling med faktor VII
EP2046372A2 (de) * 2006-07-17 2009-04-15 Novo Nordisk Health Care AG Faktor-viia-analoga mit erhöhter aktivität zur behandlung von thrombozytopenie
EP2147096B1 (de) * 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modifizierte Faktor-VII-Polypeptide und Verwendungen davon
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
CA2722230C (en) 2008-04-21 2016-08-23 Novo Nordisk Health Care Ag Dry transglutaminase composition
EP2149603A1 (de) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und ihre Verwendung zur Behandlung von Blutungsstörungen
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
ES2773766T3 (es) * 2008-12-19 2020-07-14 Baxalta GmbH Inhibidores de TFPI y métodos de uso
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
CL2011001887A1 (es) * 2010-08-05 2012-02-03 Council Scient Ind Res Construcciones de proteinas quimericas que poseen propiedades anticoagulantes y tromboliticas; secuencia de acido nucleico que las codifica; vector; celula huesped; metodo de preparacion; formulacion farmaceutica que las comprende; y su uso para inhibir la trombina.
CA2867363C (en) 2012-03-21 2023-02-28 Baxter International Inc. Tfpi inhibitors and methods of use
EP2881463A1 (de) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und/oder mit erhöhter F.IX-Gerinnungsaktivität und ihre Verwendung zur Behandlung von Blutungsstörungen
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
WO2020021890A1 (ja) 2018-07-25 2020-01-30 ソニー株式会社 血液凝固系解析装置
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221780A (en) * 1978-12-04 1980-09-09 Cort Joseph H Method for producing high potency factor VIII
ATE66374T1 (de) * 1985-11-26 1991-09-15 Novo Nordisk As Zubereitungen und verfahren zur behandlung von blutungsstoerungen.
US5622988A (en) * 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
WO1993006855A1 (en) * 1991-10-11 1993-04-15 Novo Nordisk A/S Hemostatic composition for local hemostasis
EP0624095B2 (de) * 1991-12-31 2005-07-20 Zymogenetics, Inc. Verfahren und zusammensetzungen zur verminderung von blutverlust
WO1994002172A1 (en) * 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
DE4429118C2 (de) * 1994-08-17 1997-01-16 Siemens Ag Radarsensor
EP0885020A1 (de) * 1996-02-20 1998-12-23 Cohesion Corporation Verbindungen zum gewebeverschluss und methoden zu deren gebrauch
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
AU2094199A (en) * 1997-12-23 1999-07-12 Nuvas Llc Thrombogenic polypeptide chimeras and conjugates having activity dependent upon association with tumor vascular endothelium
EP1076698A2 (de) * 1998-05-14 2001-02-21 Battelle Memorial Institute Menschliche blutgerinnungsfaktoren aus transgenen pflanzen
EP1148427A1 (de) * 2000-04-21 2001-10-24 Koninklijke KPN N.V. Methode und System zur Erzeugung eines Lesezeichen-Knopfs in einem Web-Browser mit der Darstellung eines vom Benutzer ausgewählten Teils der zugehörigen Datei
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
PL365290A1 (en) * 2001-02-05 2004-12-27 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor ix polypeptides
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
WO2003039582A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocapronic acid
JP2005510515A (ja) * 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびプロテインｃ阻害剤を含む薬学的組成物
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物

Also Published As

Publication number Publication date
EP1282439B1 (de) 2005-11-30
WO2001085199A1 (en) 2001-11-15
CN1304049C (zh) 2007-03-14
AU2001258228B2 (en) 2006-01-12
US20070280920A1 (en) 2007-12-06
DK1282438T3 (da) 2005-11-14
ES2247106T3 (es) 2006-03-01
JP2004505016A (ja) 2004-02-19
ES2254414T3 (es) 2006-06-16
IL152554A0 (en) 2003-05-29
CN1429117A (zh) 2003-07-09
US20030092627A1 (en) 2003-05-15
NO20025355D0 (no) 2002-11-08
CA2406583A1 (en) 2001-11-15
EP1593389A1 (de) 2005-11-09
HUP0301868A3 (en) 2006-11-28
ATE300953T1 (de) 2005-08-15
AU2001258230A1 (en) 2001-11-20
NO20025355L (no) 2003-01-09
AU5822801A (en) 2001-11-20
CZ20023667A3 (cs) 2003-04-16
EP1282438A1 (de) 2003-02-12
WO2001085198A1 (en) 2001-11-15
BR0110659A (pt) 2003-02-11
EP1282439A1 (de) 2003-02-12
ATE311198T1 (de) 2005-12-15
HUP0301868A2 (hu) 2003-08-28
DE60112429T2 (de) 2006-06-01
DE60115422D1 (de) 2006-01-05
EP1282438B1 (de) 2005-08-03
DE60115422T2 (de) 2006-08-17
PL365042A1 (en) 2004-12-27
US20060199766A1 (en) 2006-09-07
JP2003532684A (ja) 2003-11-05

Similar Documents

Publication Publication Date Title
DE60112429D1 (de) Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen
DE69939370D1 (de) Medizinischer artikel aus unterschiedlich hergestelltem kollagen-biomaterial
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
DE69826267D1 (de) Haarwuchszusammensetzungen und deren verwendungen
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
ATE217187T1 (de) Neue pharmazeutische zusammensetzung, die den ace-hemmer ramipril und eine dihydropyridin- verbindung enthält
DK1296633T3 (da) Medicinalproduktpakning til udryddelsesbehandling
ATE257386T1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
BR0307696A (pt) Composição desodorante ou antitranspirante
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
EA200400436A1 (ru) Медикаменты для профилактики и лечения бромидроза
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
ES2044100T4 (es) Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.
DE69331008D1 (de) Verwendung von cotinin zur linderung des tabakentzugssyndrom
ATE470671T1 (de) Verbindungen mit wachstumshormon-freisetzender eigenschaft
ATE382367T1 (de) Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern
FI950010A (fi) Bradykiniiniantagonistien käyttö lääkeaineiden valmistamiseksi virussairauksien hoitamiseksi
DE59407576D1 (de) Verwendung von Etofibrat und pharmazeutische Zusammensetzungen, enthaltend Etofibrat, zur Behandlung der diabetischen Angio- und Retinopathie
ATE367824T1 (de) Faktor xiii in kombination mit faktor ix zur behandlung von hämophilie b
ATE314073T1 (de) Kombination von aktiva mit alfuzosin und apomorphin
ITMI910442U1 (it) Struttura di zoccolo ortopedico, o simile, in particolare per la preve nzione o la cura del valgismo dell'alluce.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition